De Nicolò Amedeo, Cantù Marco, D'Avolio Antonio
Laboratory of Clinical Pharmacology & Pharmacogenetics, Unit of Infectious Diseases, Department of Medical Sciences, 'Amedeo di Savoia' Hospital, University of Turin, 10149 Turin, Italy.
Department of Laboratory Medicine EOLAB, Laboratory of Clinical Biochemistry & Pharmacology, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Bioanalysis. 2017 Jul;9(14):1093-1105. doi: 10.4155/bio-2017-0059. Epub 2017 Jul 24.
LC-MS is becoming a standard for many applications, thanks to high sensitivity and selectivity; nevertheless, some issues are still present, particularly due to matrix effect (ME). Considering this, the use of optimal internal standards (ISs, usually stable-isotope labeled) is important, but not always possible because of cost or availability. Therefore, a deep investigation of the inter-lot variability of the ME and of the correcting power of the chosen IS (isotope-labeled or not) is mandatory. While the adoption of isotopically labeled ISs considered as a 'gold standard' to mitigate ME impact on analytical results, there is not consensus about the standard technique to evaluate it during method validation. In this paper, currently available techniques to evaluate, reduce or counterbalance ME are presented and discussed. Finally, these techniques were summarized in a flowchart for a robust management of ME, particularly considering the concept of 'internal standard normalized ME'.
由于具有高灵敏度和选择性,液相色谱-质谱联用(LC-MS)正成为许多应用的标准方法;然而,一些问题仍然存在,特别是由于基质效应(ME)。考虑到这一点,使用最佳内标(ISs,通常为稳定同位素标记)很重要,但由于成本或可用性,并非总是可行。因此,必须深入研究基质效应的批次间变异性以及所选内标的校正能力(无论是否为同位素标记)。虽然采用同位素标记的内标被视为减轻基质效应影响分析结果的“金标准”,但在方法验证期间评估它的标准技术尚无共识。本文介绍并讨论了目前用于评估、减少或抵消基质效应的技术。最后,这些技术被总结在一个流程图中,用于稳健地管理基质效应,特别是考虑到“内标归一化基质效应”的概念。